Originalspråk | engelska |
---|---|
Tidskrift | Haematologica |
Volym | 107 |
Nummer | 8 |
Sidor (från-till) | 1971-1976 |
Antal sidor | 6 |
ISSN | 0390-6078 |
DOI | |
Status | Publicerad - aug. 2022 |
MoE-publikationstyp | B1 Artikel i en vetenskaplig tidskrift |
Vetenskapsgrenar
- 3111 Biomedicinska vetenskaper
- 3122 Cancersjukdomar
Åtkomst av dokument
Citera det här
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. / Hohtari, Helena; Pallisgaard, Niels; Kankainen, Matti et al.
I: Haematologica, Vol. 107, Nr. 8, 08.2022, s. 1971-1976.Forskningsoutput: Tidskriftsbidrag › Brev › Vetenskaplig
TY - JOUR
T1 - Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
AU - Hohtari, Helena
AU - Pallisgaard, Niels
AU - Kankainen, Matti
AU - Ellonen, Pekka
AU - Brück, Oscar
AU - Siitonen, Timo
AU - Säily, Marjaana
AU - Sinisalo, Marjatta
AU - Pyörälä, Marja
AU - Itälä-Remes, Maija
AU - Koskenvesa, Perttu
AU - Elonen, Erkki
AU - Mustjoki, Satu
AU - Porkka, Kimmo
N1 - Funding Information: NGS library preparation, sequencing and sequence analysis were performed by the Institute for Molecular Medicine Finland (FIMM) Technology Center, University of Helsinki. We thank laboratory technicians Jay Klievink in Hematology Research Unit Helsinki (HRUH) and Minna Suvela in FIMM for technical support with the DNA extractions and laboratory coordinator Minna Tuominen in FIMM for technical support with multiplex ligation-dependent probe amplification. We are grateful to the members of the HRUH for discussions and technical help. We thank research nurses Anne Gesterberg, Jenni Raali and Susanna Helkkula for help with clinical data. We thank Dr Veli Kairisto in Tykslab, Dr Taru Kuittinen in Kuopio University Hospital and clinical laboratory geneticists Anne Juvonen and Tarja Salonen in HUSLAB for help with clinical samples. The samples of this project were provided by Finnish University Hospital clinical laboratories and the Finnish Hematology Registry and Clinical Biobank (FHRB) with appropriate ethics approval (Dnro 202/06.01.00/2013). We thank all the patients for their generous participation. The FHRB Biobank is supported by the Finnish Association of Hematology, the Finnish Red Cross Blood Service, Institute for Molecular Medicine Finland, and the participating hospitals in Finland. This study was supported by the Doctoral Program in Clinical Research at the University of Helsinki and personal grants (to HH) from Emil Aaltonen Foundation, Ida Montin Foundation, Blood Disease Research Foundation, Finnish Hematology Association, Finnish Medical Foundation, Biomedicum Helsinki Foundation, Paulo Foundation, (to SM) Finnish Cancer Organizations, Sigrid Juselius Foundation, Signe and Ane Gyllenberg Foundation, Relander Foundation, and state funding for university-level health research in Finland. The laboratory analytics costs of this study were funded by Incyte. Funding Information: TS (not related to this study) is a member of the advisory board of Celgene and AbbVie; is a member of the advisory board of and received lecture fees from Pfizer and Janssen-Cilag; received lecture fees from Bristol Myers Squibb; received congress fees from and is a member of the advisory board of Novartis; received congress fees from Amgen. MP (not-related to this study) is a member of the advisory board of Pfizer and AbbVie; received lecture and congress fees from Novartis. OB received consultancy fees from Novartis and Sanofi. SM (not related to this study) received research funding from Novartis, BMS, Janpix, and Pfizer. All other authors have no conflicts of interest to disclose. Funding Information: NGS library preparation, sequencing and sequence analysis were performed by the Institute for Molecular Medicine Finland (FIMM) Technology Center, University of Helsinki. We thank laboratory technicians Jay Klievink in Hematology Research Unit Helsinki (HRUH) and Minna Suvela in FIMM for technical support with the DNA extractions and laboratory coordinator Minna Tuominen in FIMM for technical support with multiplex ligation-dependent probe amplification. We are grateful to the members of the HRUH for discussions and technical help. We thank research nurses Anne Gesterberg, Jenni Raali and Susanna Helkkula for help with clinical data. We thank Dr Veli Kairisto in Tykslab, Dr Taru Kuittinen in Kuopio University Hospital and clinical laboratory geneticists Anne Juvonen and Tarja Salonen in HUSLAB for help with clinical samples. The samples of this project were provided by Finnish University Hospital clinical laboratories and the Finnish Hematology Registry and Clinical Biobank (FHRB) with appropriate ethics approval (Dnro 202/06.01.00/2013). We thank all the patients for their generous participation. The FHRB Biobank is supported by the Finnish Association of Hematology, the Finnish Red Cross Blood Service, Institute for Molecular Medicine Finland, and the participating hospitals in Finland.
PY - 2022/8
Y1 - 2022/8
KW - 3111 Biomedicine
KW - 3122 Cancers
U2 - 10.3324/haematol.2021.280578
DO - 10.3324/haematol.2021.280578
M3 - Letter
C2 - 35484650
AN - SCOPUS:85135419364
VL - 107
SP - 1971
EP - 1976
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 8
ER -